Viva Biotech Holdings Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Viva Biotech Holdings han disminuido a una tasa media anual de -23.5%, mientras que en la industria Life Sciences los beneficios crecieron en un 20.8% anualmente. Los ingresos han ido creciendo a una tasa media de 32.6% al año.

Información clave

-23.5%

Tasa de crecimiento de los beneficios

-22.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences	41.4%
Tasa de crecimiento de los ingresos	32.6%
Rentabilidad financiera	0.8%
Margen neto	-0.02%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

Oct 14

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Aug 30

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21

Desglose de ingresos y gastos

Cómo gana y gasta dinero Viva Biotech Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SEHK:1873 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 24	1,995	0	389	94
31 Mar 24	2,075	-58	403	111
31 Dec 23	2,156	-116	418	128
30 Sep 23	2,284	-276	417	150
30 Jun 23	2,413	-436	416	172
31 Mar 23	2,396	-482	413	154
31 Dec 22	2,380	-528	410	136
30 Sep 22	2,283	-209	398	116
30 Jun 22	2,186	111	385	96
31 Mar 22	2,145	199	353	94
31 Dec 21	2,104	288	322	92
30 Sep 21	1,815	258	271	87
30 Jun 21	1,526	228	219	81
31 Mar 21	1,111	-79	171	74
31 Dec 20	697	-387	123	66
30 Sep 20	538	-349	96	59
30 Jun 20	378	-311	70	52
31 Mar 20	351	-23	62	48
31 Dec 19	323	266	55	45
30 Sep 19	299	176	48	37
30 Jun 19	275	86	42	30
31 Mar 19	243	88	36	27
31 Dec 18	210	91	30	25
31 Dec 17	148	76	17	17
31 Dec 16	96	24	14	17

Ingresos de calidad: 1873 actualmente no es rentable.

Margen de beneficios creciente: 1873 actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 1873 no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 23.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 1873 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 1873 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Life Sciences (-3.9%).

Rentabilidad financiera

Alta ROE: 1873 tiene una rentabilidad financiera negativa (0.81%), ya que actualmente no es rentable.

Viva Biotech Holdings Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: EPS: CN¥0.055 (vs CN¥0.001 in 1H 2023)

Viva Biotech Holdings to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Recent updates

Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

New minor risk - Share price stability

First half 2024 earnings released: EPS: CN¥0.055 (vs CN¥0.001 in 1H 2023)

Viva Biotech Holdings Announces Chief Financial Officer Changes

Viva Biotech Holdings (SEHK:1873) commences an Equity Buyback Plan for 216,136,630 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2024.

Viva Biotech Holdings (SEHK:1873) commences an Equity Buyback Plan for 216,136,630 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2024.

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Viva Biotech Holdings to Report First Half, 2024 Results on Aug 29, 2024

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

New minor risk - Share price stability

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

New major risk - Revenue and earnings growth

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023

Viva Biotech Holdings announced that it has received HKD 470 million in funding

Executive VP & Executive Director recently bought HK$226k worth of stock

New minor risk - Share price stability

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Viva Biotech Holdings Announces Board Changes

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021)

Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022

Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Full year 2021 earnings: Revenues miss analyst expectations

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Executive VP & Executive Director recently bought HK$1.1m worth of stock

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020)

Insider recently sold HK$345m worth of stock

Executive Director Fengmao Hua has left the company

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Executive Director & CFO recently sold HK$257m worth of stock

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019)

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021

Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020